StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Syndax Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Syndax Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $273.00M, up 11.1% year over year. For fiscal 2025 it was $258.78M, up 7.1% from the year before. Over ten years it grew 39.1% a year on average. The highest annual figure on record is $258.78M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$258.78M+7.1%
FY2024Dec 31, 2024$241.65M+48.2%
FY2023Dec 31, 2023$163.03M+37.6%
FY2022Dec 31, 2022$118.50M+34.3%
FY2021Dec 31, 2021$88.25M+75.0%
FY2020Dec 31, 2020$50.44M+17.3%
FY2019Dec 31, 2019$42.99M-28.5%
FY2018Dec 31, 2018$60.11M+24.7%
FY2017Dec 31, 2017$48.20M+52.2%
FY2016Dec 31, 2016$31.67M+231.6%
FY2015Dec 31, 2015$9.55M-6.2%
FY2014Dec 31, 2014$10.18M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$67.48M+19.9%
Q2 FY2026Jun 30, 2026$68.04M+9.3%
Q1 FY2026Mar 31, 2026$58.85M-4.5%
Q4 FY2025Dec 31, 2025$78.64M+20.0%
Q3 FY2025Sep 30, 2025$56.28M-20.7%
Q2 FY2025Jun 30, 2025$62.23M+27.9%
Q1 FY2025Mar 31, 2025$61.64M+9.1%
Q4 FY2024Dec 31, 2024$65.53M+18.9%
Q3 FY2024Sep 30, 2024$70.97M+81.6%
Q2 FY2024Jun 30, 2024$48.66M+40.0%
Q1 FY2024Mar 31, 2024$56.49M+65.9%
Q4 FY2023Dec 31, 2023$55.13M+73.1%
Q3 FY2023Sep 30, 2023$39.09M+45.3%
Q2 FY2023Jun 30, 2023$34.76M+16.9%
Q1 FY2023Mar 31, 2023$34.05M+13.4%
Q4 FY2022Dec 31, 2022$31.84M+33.2%
Q3 FY2022Sep 30, 2022$26.90M+5.1%
Q2 FY2022Jun 30, 2022$29.73M+76.2%
Q1 FY2022Mar 31, 2022$30.02M+37.3%
Q4 FY2021Dec 31, 2021$23.90M+54.0%
Q3 FY2021Sep 30, 2021$25.61M+77.7%
Q2 FY2021Jun 30, 2021$16.87M+54.2%
Q1 FY2021Mar 31, 2021$21.87M+128.7%
Q4 FY2020Dec 31, 2020$15.52M+63.4%
Q3 FY2020Sep 30, 2020$14.41M+45.2%
Q2 FY2020Jun 30, 2020$10.94M-11.0%
Q1 FY2020Mar 31, 2020$9.56M-15.2%
Q4 FY2019Dec 31, 2019$9.50M-39.9%
Q3 FY2019Sep 30, 2019$9.92M-29.6%
Q2 FY2019Jun 30, 2019$12.29M-17.2%
Q1 FY2019Mar 31, 2019$11.28M-26.5%
Q4 FY2018Dec 31, 2018$15.82M-4.7%
Q3 FY2018Sep 30, 2018$14.10M+15.6%
Q2 FY2018Jun 30, 2018$14.85M+50.6%
Q1 FY2018Mar 31, 2018$15.34M+60.6%
Q4 FY2017Dec 31, 2017$16.60M+95.9%
Q3 FY2017Sep 30, 2017$12.19M–
Q2 FY2017Jun 30, 2017$9.86M–
Q1 FY2017Mar 31, 2017$9.55M–
Q4 FY2016Dec 31, 2016$8.47M–

More Syndax Pharmaceuticals figures

See a number that looks wrong?